Trial Profile
Oral cannabidivarin (CBDV) solution for treatment of HIV-associated neuropathic pain – a randomized, double-blind, placebo-controlled phase II study.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Aug 2020
Price :
$35
*
At a glance
- Drugs Cannabidivarin (Primary)
- Indications Neuropathic pain
- Focus Therapeutic Use
- 08 Aug 2020 Primary endpoint (pain intensity on an 11-point numeric rating scale) has not been met as per results published in the Clinical Pharmacology and Therapeutics.
- 08 Aug 2020 Results published in the Clinical Pharmacology and Therapeutics
- 16 Feb 2020 Status changed from recruiting to completed.